ETON logo

ETON PHARMACEUTICALS INC

ETONNASDAQ
🏆 #2149 by market capEarnings Nov 9US Equity
$813.04▼ $8.46 (−1.04%)
Simulated price
🔔
Track ETON
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.62B
Small Cap
📈Revenue Growth (YoY)
+104.9%
High Growth
📊Gross Margin
57.9%
Healthy
💵FCF Margin
13.9%
Healthy
⚖️P/S Ratio
15.4x
Expensive
Otter Score
44
Weak
No chart data available for ETON.

Trading Snapshot

Day Range
$806.02 – $823.08
52-Week Range
$14.27 – $66.37
Volume
$2.28B
Avg Volume
$2.27B
Shares Outstanding
27.4M
Next Earnings
Nov 22, 2026

Fundamentals Snapshot

Annual Revenue
$80M
Last Q Revenue
$38M
P/E Ratio
127.3
P/S Ratio
15.4x
EPS (TTM)
$0.46
Dividend Yield
0.00%
Dilution (1yr)
+3.0%

Why Investors Own ETON

  • ✓High-growth profile — revenue up +14.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 31% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ETON logo

ETON PHARMACEUTICALS INC

ETON
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$80M▲ +104.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
53.5%▼ −10.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$72K▼ −102.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$10M▲ +980.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
26.9M▲ +3.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$17M▲ +$32M YoY
StockOtter · stockotter.space

About ETON PHARMACEUTICALS INC

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$881.94
▲ +8.5% Upside
High Target$1,002.07
Low Target$704.47
Based on 10 analysts

Latest News & Updates

🚀
CNBC·2h ago

ETON PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift ETON price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

ETON PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.